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Abstract
Background: Clinical trials of immunologic therapies provide opportunities to study the cellular and molecular
effects of those therapies and may permit identification of biomarkers of response. When the trials are performed
at multiple centers, transport and storage of clinical specimens become important variables that may affect
lymphocyte viability and function in blood and tissue specimens. The effect of temperature during storage and
shipment of peripheral blood on subsequent processing, recovery, and function of lymphocytes is understudied
and represents the focus of this study.
Methods: Peripheral blood samples (n = 285) from patients enrolled in 2 clinical trials of a melanoma vaccine
were shipped from clinical centers 250 or 1100 miles to a central laboratory at the sponsoring institution. The yield
of peripheral blood mononuclear cells (PBMC) collected before and after cryostorage was correlated with
temperatures encountered during shipment. Also, to simulate shipping of whole blood, heparinized blood from
healthy donors was collected and stored at 15°C, 22°C, 30°C, or 40°C, for varied intervals before isolation of PBMC.
Specimen integrity was assessed by measures of yield, recovery, viability, and function of isolated lymphocytes.
Several packaging systems were also evaluated during simulated shipping for the ability to maintain the internal
temperature in adverse temperatures over time.
Results: Blood specimen containers experienced temperatures during shipment ranging from -1 to 35°C. Exposure
to temperatures above room temperature (22°C) resulted in greater yields of PBMC. Reduced cell recovery
following cryo-preservation as well as decreased viability and immune function were observed in specimens
exposed to 15°C or 40°C for greater than 8 hours when compared to storage at 22°C. There was a trend toward
improved preservation of blood specimen integrity stored at 30°C prior to processing for all time points tested.
Internal temperatures of blood shipping containers were maintained longer in an acceptable range when warm
packs were included.
Conclusions: Blood packages shipped overnight by commercial carrier may encounter extreme seasonal temperatures.
Therefore, considerations in the design of shipping containers should include protecting against extreme ambient
temperature deviations and maintaining specimen temperature above 22°C or preferably near 30°C.
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Cell-based immunological assays are integral to moni-
toring the effects of immunotherapy clinical trials. The
main clinical specimen obtained for these assays is
whole blood collected in heparinized vacutainer tubes
from which peripheral blood mononuclear cells (PBMC)
are isolated. Assays of cellular immune responses to
immune therapy depend on functional and viable
PBMC. It is critical that outside factors, other than
study parameters, do not introduce significant variability
in the immune assays due to compromised PBMC integ-
rity. Therefore, trials utilizing multiple clinical centers
present challenges in how to best process and transport
whole blood and tissue samples.
The need for specific guidelines for the shipment of
biological specimens is of great concern for the conduct
of multi-center clinical trails at the national and interna-
tional level [1-3]. Both complex processing and delay
before processing by individual laboratories increase the
variability in specimen performance [4]. In contrast,
central laboratory processing lessens the variability
introduced by multiple processing protocols but is more
costly and may not be available for all investigators. It
therefore becomes a critical issue in the design of multi-
center clinical trials to determine whether biological
specimens should be processed immediately, the same
day, or after shipment to a central laboratory.
Early studies have demonstrated how time and tem-
perature of storage affect lymphocyte viability and phe-
notype when whole blood is stored overnight at 4°C
[5-7]. Storage at room temperature prior to processing
also affects viability and blastogenic responses [8] as
well as lymphocyte separation by Ficoll density centrifu-
gation [9,10]. The importance of establishing standard
shipping parameters has been stressed in the infectious
disease setting, in which a profound impact of shipping
was noted on the lymphoproliferative responses to
microbial antigens in both HIV-infected and healthy
donors [11,12]. Single cell-based techniques such as ELI-
spot assays [13-15], intracellular cytokine staining
[16-19], and HLA-specific multimeric assays [20-22] are
widely used and depend on optimal conditions for speci-
men handling in order to detect rare populations of
peptide specific lymphocytes in response to immu-
notherapy. Several studies have confirmed that cryopre-
served PBMC can be used reliably in these assays
[23-26]. Use of cryopreserved samples, however,
depends on optimal sample handling before and after
cryopreservation. Some studies have defined optimal
time intervals between venipuncture and cryopreserva-
tion [26-29] and optimal conditions for freezing [30].
Also, handling and storage of cryopreserved PBMC have
been evaluated, showing that fluctuations in sub-zero
freezing temperatures can alter the viability and function
of recovered lymphocytes; shipping conditions for frozen
samples have also been addressed [31,32]. However, the
effect of ambient temperature changes during shipping
or storage prior to cryopreservation has not been
addressed.
It has been suggested that an interval of whole blood
storage exceeding 8 hours (h) causes a significant
decrease in cellular immune function [27]. This finding
provides rationale for immediate isolation and cryopre-
servation of PBMC at each participating clinical center
and indeed, optimization of cryopreservation media and
of thawing practices has improved recovery of immuno-
logical responses at the single cell level [25,30]. How-
ever, processing of blood and cryopreservation of PBMC
at off-site locations is expensive and requires oversight
and quality control of the processing lab at each center.
Thus, for many multicenter clinical trials of cancer vac-
cines and other therapies, all off-site whole blood speci-
mens are shipped to a central laboratory according to a
standard operating protocol, and monitored strictly for
quality control and quality assurance. Our concern that
shipping whole blood in different seasons, in various cli-
mates, may impact PBMC viability and function
prompted this study. Specifically, we have addressed the
effect of shipping temperatures on cell viability, recovery
and function, and have modeled these in vitro when
controlling for temperature.
Methods
Blood collection, processing and storage
Patients’ blood specimens were derived from partici-
pants enrolled in one of three studies. Participants were
enrolled in the clinical studies following informed con-
sent, and with Institutional Review Board for Health
Sciences Research approval (IRB-HSR# 10598, 10524,
and11491) and review by the FDA (BB-IND# 9847 and
12191). Patients’ blood specimens from 2 clinical trials
(HSR# 1524(HSR# 10524 and 11491) were monitored
during a 9 month period from late summer, through
fall, winter and early spring. Two hundred and eighty-
five blood specimens collected at participating clinical
trial centers in Houston, TX and Philadelphia PA, were
shipped to Charlottesville VA. Clinical laboratory ana-
lyses, including complete blood counts (CBC) and differ-
ential hematological counts, were performed at the
individual centers and the results incorporated into a
trial database. An additional 60 ml of blood were col-
lected in 10cc heparinized vacutainer tubes (BDBios-
ciences, Franklin Lakes, NJ) and were shipped, in
insulated packaging, by overnight courier at ambient
temperature to the Biorepository and Tissue Research
Facility (BTRF) at the University of Virginia (UVa) for
processing and cryo-preservation, on the day they
arrived, for future immunological testing in cell-based
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continuously monitored using the TempCheck Sensor
(Marathon Products, Inc., San Leandro, CA) to deter-
mine the temperature range to which blood samples
were exposed when shipped overnight by commercial
carrier, and to evaluate the effects of those temperatures
on cell yield. Temperature gauges recorded the maxi-
mum and minimum temperatures attained inside the
packages during shipment. Blood drawn at UVa was
processed either the same day or the following day,
depending on when in the day it was drawn. The
volume of blood collected, and the number of viable
PBMC isolated were recorded by the BTRF. These
values were used to determine the cell yield before cryo-
preservation. In all cases, the PBMC fraction of whole
blood was collected from Leucosep™ (Greiner Bio-One,
Monroe, NC) tubes following centrifugation for 10 min-
utes at 1000 × g.
The expected cell yield for each sample was calculated
from the CBC and differential tests performed on whole
blood at the originating clinical laboratory. The absolute
lymphocyte and absolute monocyte counts calculated
from the CBC and differential were combined and mul-
tiplied by the volume of blood collected to represent the
expected total PBMC in the blood (expected cell yield).
Additional File 1 provides a table of cell count data
from each center. The table shows the calculated per-
centage (mean, median, and quartiles) of lymphocytes
and monocytes derived from differential and complete
cell counts. The number of PBMC isolated by Ficoll
separation, divided by the expected cell yield provides
the ratio cell yield. Ratio cell yields of less than 1 are
expected due to losses in Ficoll separation. However,
b e c a u s et h eF i c o l ls e p a r a t i o n sw e r ed o n eb yt h es a m e
central laboratory and according to a consistent proto-
col, differences in ratio cell yields in different subgroups
of specimens are primarily attributed to effects of ship-
ping conditions.
Incubation conditions for whole blood
In one set of experiments, approximately 7-8 ml whole
blood were collected into each of eleven heparinized
vacutainer tubes from six healthy donors according to
IRB protocol 10598 and were labelled to define the tem-
perature conditions to which they would be exposed.
Each tube was incubated at various temperatures over a
2 4hp e r i o da tc o n d i t i o n si n t e n d e dt om o d e lw h a tm a y
happen in overnight shipping conditions (Additional File
2). After a 1-2 h equilibration period at room tempera-
ture (RT, 22°C), tubes from each sample were placed in
each of the 4 conditions: (a) temperature-controlled
refrigerated centrifuge set at 15°C, (b) 22°C as a control
condition, (c) water bath set at 30°C, or (d) water bath
set at 40°C. In addition, one tube was placed in a 50°C
water bath for 2 h, but this condition invariably led to
hemolysis and the samples were not evaluable. For each
temperature condition (other than RT), one tube
was exposed to that low or high temperature for 2, 8 or
12 h, and then each was returned to RT for the remain-
ing 24 h study period. Thus, one tube served as an
untreated control and was at kept at RT for the whole
24 h. After these incubations, PBMC were isolated from
each blood sample by Ficoll density gradient as
described above. Viable cell numbers were determined
by trypan dye exclusion. PBMC were cryopreseved in
freezing medium (90% FCS, 10% DMSO) overnight at
-80°C, then transferred to vapor phase liquid nitrogen
for 1-4 weeks before thawing for analysis.
ELIspot Assay
Cells producing IFNg after antigen specific and non-
specific stimulation were enumerated by ELIspot assay
as described previously [33,34]. In brief, PBMC were
thawed in pre-warmed RPMI1640 (Invitrogen, Carlsbad
CA) containing 10% human AB serum (HuAB; Gemini)
and 100 Units/mL of DNase I (Worthington Biochem-
ical Corp., Lakewood, NJ). Cells were centrifuged at
350 × g and adjusted to the desired cell density in
RPMI 1640 supplemented with 10% HuAB serum and
plated into PVDF-membrane plates coated with anti-
interferon gamma antibody (Pierce-Endogen, Thermo
Scientific, Rockford IL). Phytohemagglutinin (PHA),
phorbol myristate acetate (PMA and ionomycin were
obtained from Sigma-Aldrich (St. Louis, MO). A pool of
35 MHC Class I restricted peptides consisting of pep-
tides from cytomegalovirus, Epstein-Barr and influenza
virus proteins (CEF peptide pool; [35]; Anaspec, Fre-
mont CA) or media alone were added in quadruplicate
a n dc u l t u r e si n c u b a t e do v e r n i g h ta t3 7 ° Ci na5 %C O 2
atmosphere. Spots were developed according to standard
protocol and enumerated on a BioReader 4000 (Bio-Sys,
Karben, Germany) plate reader.
Flow cytometry
CD3, CD4, CD8 and CD56 positive lymphocyte popula-
tions were enumerated by flow cytometry using fluores-
cent-labelled antibodies (BDBiosciences, San Diego, CA).
Cells were washed, suspended in PBS (Invitrogen) con-
taining 0.1% BSA (Sigma) and 0.1% sodium azide
(Sigma). Titrated amounts of each reagent were added to
cells, incubated, washed free of excess stain, and fixed in
paraformaldehyde. To determine whether there was an
increase in apoptosis due to different storage conditions,
thawed PBMC were incubated overnight at 37°C in 5%
CO2 in RPMI 1640 + 10% Human AB serum. The next
day, PBMC were surface stained with fluorescently
labeled antibodies to CD3, CD4, and CD8, then stained
with Annexin V according to manufacturer’s instructions
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micals, Inc., Gibbstown, NJ) to determine the level of
apoptosis [36-38]. Cells were acquired on a FACSCalibur
flow cytometer maintained by the Flow Cytometry core
facility of the University of Virginia. Data were analyzed
with FlowJo software (Treestar, Ashland OR).
Testing of Blood Shipping Packages
The standard shipping container used in our clinical
trials was obtained from Safeguard Technologies Corp.
(Conshohocken, PA). It consisted of a white corrugated
box fitted with a hydrophilic foam-lined clear plastic
snap-lock case inserted into a plastic zip lock bag. This
was placed inside a cardboard shipping container lined
with 1” thick Styrofoam. An alternate packaging design
was provided by JVI (Charlottesville VA) and consisted
of a 14” ×1 1 ” ×5 ” box of 200# corrugated cardboard
insulated with Control Temp Packaging foam of 1”
thickness. Inside was placed a 12” ×9 ” ×3 ” clamshell
type clear plastic box containing an 11” ×8 . 5 ” ×5 / 8 ”
foam vial holder.
Each type of shipping container was tested for its abil-
ity to maintain temperature in cold ambient conditions
(e.g.: during winter months). Forty heparinized vacutai-
ners were filled with water and equilibrated to 37°C.
Ten vacutainers were placed inside each of 4 packages
(2 of each type). Each package type received a gel pack
c o n d i t i o n e da te i t h e r3 7 ° Co r2 2 ° Cw h i c hw a st h e n
placed alongside the vacutainer holder. One probe of an
indoor/outdoor thermometer (Taylor Precision Pro-
ducts, Oak Brook IL) was placed inside the package
while another remained outside to monitor external
ambient temperature. Packages were placed either in a
cold room at 4°C for a minimum of 12 h or were
handled in a manner to model the experience of a pack-
age being shipped via motor vehicle overnight in a non-
heated compartment. Temperatures were recorded every
15 minutes during the first hour, and 30-60 minutes
thereafter.
Additional testing of the JVI packaging material was
performed by R.N.C. Industries Inc. (Norcross GA
30071) at high external package temperature. The clam-
shell foam holder containing vials of liquid was placed
inside the package. Two 12 oz Control Temp gel packs
conditioned at 20°C were placed in the clamshell onto
which the foam vial holder (including the 1/4” foam
above and below) containing five 5/8” vials filled with
water conditioned at 20°C was placed inside. The pack-
age was closed, put at 45°C and the internal package
temperature was monitored for 48 hours using an
Omega OMB-DAQ-55 USB data acquisition system,
serial number #156772. T thermocouples were cali-
brated 2 months earlier using a stirred water bath
calibration.
Statistical analysis
The MIXED procedure in SAS 9.1.3 (SAS Institute,
Cary, NC) was used to analyze the effects of tempera-
ture (3 levels) and duration (3 levels) on outcomes
including ELIspot, phenotype, and viability. These effects
were modeled jointly (main effects plus interactions) for
each outcome measure and outcome measurements
were first normalized by division of the raw data by the
donor value at RT for 24 h. Since donors served as
blocks and contributed an observation from each condi-
tion (i.e. each combination of temperature and duration
level), intra-donor correlation was modeled assuming a
compound symmetry structure in the residual covar-
iance matrix. Degrees of freedom were calculated using
the Kenward-Roger method. To assess the effects of sto-
rage under different temperature conditions on apopto-
sis among CD4 and CD8 populations, a modeling
scheme similar to the one above was performed using
calculated logits as the outcome measure. This is
defined as the loge([pi/1-pi]/[pc/1-pc]) where p = the
proportion of cells that are apoptotic or necrotic (as
defined by Annexin V and 7AAD staining); i = the sto-
rage conditions of the whole blood specimen; and c =
the storage condition of the control specimen at RT for
24 hours. All tests were assessed at a = 0.05.
Results
Effect of shipping temperatures and extreme changes in
temperature on the cell yield for clinical trial specimens
Package temperatures were lowest in winter months and
highest in summer months, suggesting that the tempera-
tures experienced during shipping varied by ambient
seasonal temperatures (Figure 1A). The extreme tem-
peratures ranged from about -1°C to 35°C with 91% fall-
ing completely within the range of 4°C and 32°C.
There was a trend to lower PBMC yields in colder
months from November through February (Figure 1B),
although outliers were noted. Lower minimum temperature
was associated with lower cell yield (p = 0.001, Figure 2A),
whereas higher maximum temperature correlated with
higher cell yield (p = 0.04, Figure 2B). The range in shipping
temperatures during the winter was typically bounded by a
high temperature of 22°C, and during the warmer months
by 22°C as a low temperature. The maximum change
(deviation) in temperature from 22°C observed during ship-
ment was determined using the high or low temperature
furthest from 22°C. This represents an estimate of the
degree of temperature fluctuation encountered during ship-
ment and is plotted against the yield in Figure 2C, where
there was a correlation with warmer temperatures (p <
0.001). Overall, warmer temperatures favored greater cell
yields. These observations led us to initiate controlled in
vitro studies on the impact of storage temperature on cell
recovery, viability, and immunological function.
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cryopreservation
To determine whether exposure to extreme tempera-
tures impacts the overall integrity of PBMC, blood spe-
cimens from 6 normal volunteers were stored at
temperatures in a range encountered during blood ship-
ment or varying lengths of time and were assessed for
cell yield, cell recovery and cell function (Additional File
2). Blood was exposed to temperatures of 15°, 30°, 40°,
or 50°C for 2 h, 8 h, and 12 h and left at room tempera-
ture after that exposure for a total of 24 h after collec-
tion. Significant and unacceptable lysis and cell loss
were associated with incubation 2 h at 50°C; thus, these
were not analyzed further (unpublished observation).
Adequate data already exist for the negative effects of
refrigeration at 2-8°C [6,7,9]; so this temperature was
not assessed here. Blood stored 24 h at room tempera-
ture (22°C) was used as a reference for comparison.
A significant decrease in the PBMC cell yield was
observed for samples stored at 15°C for 12 h (p < 0.003;
Table 1). Blood stored at 30°C had PBMC yields almost
identical to the RT standard. Exposure to high or low
temperature for 8 h, followed by RT incubation was
associated with no significant decrement in cell yields at
any of the temperatures. There was a trend to lower cell
yields with 12 h at 40°C, but it was not significant.
Effect of Temperature on Cell Recovery after
cryopreservation
We hypothesized that shipping temperatures may
impact cell recovery and viability after storage in liquid
nitrogen. The total number of viable cells (trypan blue
dye exclusion) was recorded for each of the PBMC
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Figure 1 Recorded internal package temperatures during
shipment and cell yields of blood from off-site cancer centers.
(A) High (+) and low (●) package temperatures recorded between
August, 2005 through April, 2006. (B) Yield of PBMC (cell yield)
obtained from specimens shipped during this time after Ficoll
separation. The ratio cell yield is expressed as a ratio of total
number of PBMC collected after Ficoll divided by the number of
PBMC (lymphocytes and monocytes) estimated from the differential
WBC recorded on the same specimens before shipment. The
dashed line represents 100% recovery of PBMC after Ficoll as a ratio
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Figure 2 The recovery of cells after Ficoll separation increased as shipping temperature increased. (A) Correlation of the ratio cell yield
with minimum temperature during transport; p = 0.001. (B) Correlation of the ratio cell yield with maximum temperature during transport; p =
0.04. (C) Correlation of the ratio cell yield as a function of maximum temperature deviation from room temperature (22°C) during shipment;
p < 0.001
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above. Percent recovery was calculated as the ratio of
recovered viable cells to the number of viable cells initi-
ally frozen. Each condition was compared to storage at
RT for 24 h. Significant reduction of PBMC recovery
was associated with storage of blood 12 h at 15°C or 40°
C but not with either 2 h or 8 h (Table 1). However, at
30°C, the trend favored higher recoveries of PBMC, at
all time points, than that seen at RT.
Effect of temperature on viability and phenotype after
cryo-storage
These samples were also assessed by flow cytometry
for evaluable PBMC populations and the selective loss
of T lymphocyte sub-populations after cryo-preserva-
tion. Changes in the PBMC population were not
reflected in the proportion of CD4
+ and CD8
+ lympho-
cyte sub-populations (Additional file 3) or in the pro-
portion of CD56
+ lymphocytes (data not shown)
compared to that seen when whole blood is stored
overnight at RT.
However, damage to cells as a result of extreme ship-
ping temperatures may not be evident at the time of
collection or immediately after cryo-storage, but rather
during subsequent incubation [39]. Therefore, PBMC
were assessed for viability using Annexin and 7AAD to
measure apoptosis [36-38] after an overnight rest. Sig-
nificant decreases in viable PBMC (Figure 3A) were
observed in blood specimens incubated at 40°C for 8 h
(p = 0.002) and 12 h (p < 0.001). This was not seen at
the other temperature conditions tested, even at 12 h of
incubation. CD8 populations (Figure 3B) showed signifi-
cant decreases in viability at 40°C for 8 h (p = 0.013)
and after 12 h (p = 0.03). CD4 viability (Figure 3C) was
significantly reduced after 12 h at 40°C (p = 0.03). A
greater proportion of CD4 T cells (Figure 4A and 4B)
were in early stages of apoptosis (Annexin V+, 7AAD-)
whereas a greater proportion of CD8 T cells (Figure 4C
and 4D) were in the later stages of apoptosis (Annexin
V+, 7AAD+) under these same conditions. Estimates of
the odds ratio for CD4 and CD8 populations to undergo
apoptotic or necrotic cell death after exposure to 40°C
Table 1 Effect of exposure to different incubation conditions on PBMC isolation from whole blood and recovery after
cryo-preservation
Cell Yield before Cryopreservation Cell Recovery after Thawing
Exptl
RT
2h
22 h
8h
16 h
12 h
12 h
2h
22 h
8h
16 h
12 h
12 h
15°C 0.85 (0.60, 1.10)
p = 0.22
0.88 (0.63, 1.13)
p = 0.32
0.59 (0.34, 0.84)
p = 0.003
1.00 (0.70, 1.30)
p = 0.99
1.02 (0.72, 1.32) p = 0.88 0.66 (0.36, 0.97) p = 0.031
30°C 0.90 (0.65, 1.15)
p = 0.40
1.02 (0.76, 1.27)
p = 0.90
1.00 (0.75, 1.25)
p=1
1.12 (0.82, 1.42)
p = 0.41
1.20 (0.90, 1.50) p = 0.19 1.19 (0.88, 1.49) p = 0.21
40°C 0.87 (0.62, 1.12)
p = 0.30
0.83 (0.58, 1.08)
p = 0.16
0.79 (0.53, 1.06)
p = 0.12
0.91 (0.61, 1.22)
p = 0.56
0.78 (0.48, 1.08) p = 0.14 0.63 (0.32, 0.95) p = 0.026
Blood from 6 normal donors was incubated 24 h at RT (22°C, control), and for 2-12 h at 15, 22, 30 or 40°C (Exptl = Experimental), then at RT for the remainder of
24 h. PBMC were harvested and, cryopreserved, and thawed at least 1 week later. The estimated means and 95% confidence intervals of ratios of cell yield to the
control sample (RT × 24 h) are shown, both before cryopreservation and upon recovery of cells after cryopreservation. P-values are in boldface when statistically
significant.
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Page 6 of 13at 8 and 12 hours, had significance levels of p = 0.0335
and p = 0.0035 for CD4 populations, and p < 0.006 for
CD8 when compared to the control storage condition
(24 h @ RT).
Effect of temperature on cell function after cryostorage
The principal cell based assay for monitoring our clini-
cal trials of immunotherapy is the ELIspot assay which
measures specific T cell responses by enumerating T
cells secreting cytokine (IFN-gamma) after peptide sti-
mulation. We determined whether there was an adverse
effect of temperature on the function of lymphocytes in
our standard ELIspot procedure. Thawed PBMC from
each temperature condition were stimulated overnight
with PMA, PHA, or CEF or were left un-stimulated.
The following day, plates were developed and the num-
ber of spots recorded for each condition. Relative to
blood incubated overnight at RT, whole blood initially
incubated at 40°C for 8 h and 12 h resulted in signifi-
cant decreases in the number of IFN-gamma producing
T cells in response to PMA (Figure 5A; p≤004). Lower
spot counts to PHA (Figure 5B) and to CEF (Figure 5C)
were observed with whole blood exposed to either 40°C
or 15°C, respectively, for 12 h, but were not statistically
significant. Incubation at 30°C for up to 12 h was
equivalent to 22°C for measures of function by ELIspot.
Package testing in high and low ambient temperatures
Packaging was designed by JVI (Charlottesville, VA) for
shipping blood specimens in vacutainer tubes where
high or low ambient temperatures may be encountered
during shipping. Testing in our laboratory compared
the internal temperatures in shipping containers
designed by JVI with that of our prior shipping con-
tainer (SafeGuard) under winter temperature conditions.
Three of the four tests are presented in Figure 6. Pre-
warmed gel packs (RT or 37C) were included to delay a
rapid decrease in the internal temperature. Each ship-
ping container was fitted with internal and external
temperature probes and placed at 4°C or outside. In
each condition, the internal temperatures in both types
of containers fell at approximately the same rate (Figure
6A-C, representing 3 of 4 experiments that were per-
formed). The JVI shipping container, compared to the
SafeGuard container, maintained internal temperatures
above 15°C more consistently. Gel packs conditioned at
Incubation Time (h) and Temperature (C) of Whole Blood
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Figure 4 CD8 T cells show greater susceptibility to apoptosis than CD4 T cells. The percentage of cells in different stages of apoptosis was
evaluated for CD4 and CD8 T cell populations. (A) Percentage of CD4 lymphocytes in early stages of apoptosis (Annexin V+, 7AAD-) and (B) late
stages of apoptosis (Annexin V+, 7AAD+); (C) CD8 lymphocytes in early stages of apoptosis (Annexin V+, 7AAD-) and (D) late stages of apoptosis
(Annexin V+, 7AAD+). Shaded region indicates control condition as described in Figure 3.
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Page 7 of 1337°C maintained an internal temperature above 15°C for
approximately 2 hours longer than RT-conditioned gel
packs when packages were placed at a constant external
temperature of 4°C (Table 2). When exposed to outside
temperatures as would occur during shipment in winter,
gel packs pre-warmed at 37°C helped maintain an inter-
nal temperature above 15°C for 1.8 hours longer than
gel packs conditioned at room temperature. Thereafter,
the decline of the internal temperature was similar in
all packaging conditions tested. After moving the
packages to RT, the rates at which the internal tempera-
tures increased were similar for each condition (Figure
6A, C).
The effects of extreme high ambient temperatures on
maintaining internal temperatures within the range of
15-35°C was tested on the newly designed JVI shipping
container. The shipping container was placed at 45°C
(Figure 7) and for 45 hours, the temperature remained
under 35°C. For at least 21 hours, the internal tempera-
ture stayed between 20° and 30°C.
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Figure 5 Mitogen and antigen-activated PBMC responses as detected by IFNgamma secretion in an ELIspot assay. After thawing from
liquid nitrogen, PBMC were incubated 18 hours at 37°C with (A) PMA/ionomycin, (B) PHA or (C) CEF peptide pool and then tested for IFNg
secretion by ELIspot assay. Results are presented as SFC per 200,000 PBMC for PMA and PHA. CEF SFC are adjusted for the percentage of CD8+
T cells and presented as SFC per 200,000 CD8 T cells. Each condition is compared to the control condition (arrows) as described in Figure 3. (*)
p < 0.004.
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Figure 6 Internal temperature change over time in containers designed for shipping blood specimens. Ten water-filled vacutainer vials
were pre-warmed to 37°C placed inside the JVI Control Temp shipping container or in the Safeguard (SG) shipping container, surrounded with
pre-warmed gel packs, placed inside an insulated corrugated cardboard container, and sealed with tape for testing at low external temperatures.
Internal package temperatures were continuously monitored inside JVI and SG shipping containers while placed (A) at a constant low
temperature of 4°C for 22 hours followed by 22°C for 8 hours; (B) outdoors in ambient winter temperatures for 16 hours; and (C) outdoors in
ambient winter temperatures for 18 hours followed by placement of package at 22°C for 20 hours. (green diamond) External package (ambient)
temperature; internal package temperatures: (red triangle), JVI with 37°C thermal pack; (purple square), SG with 37°C thermal pack; (blue triangle),
JVI with 22°C thermal pack; (blue square), SG with 22°C thermal pack. Solid black line indicates 15°C; dashed line denotes 0°C.
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Recently much-needed attention has been given to the
conditions under which blood specimens, collected for
correlative studies of immune therapy, are handled prior
to PBMC isolation. How samples are processed and
shipped from trial sites as whole blood or separated
PBMC can affect the outcome of immunological moni-
toring of vaccine-based immunotherapeutic clinical
trials. Arguably, it is optimal to assay a blood sample
immediately and at the site where it is collected, as is
done for most routine clinical laboratory tests. However,
for novel or experimental correlative studies, this is not
usually feasible, since expertise for those tests requires
specialized laboratories. Also, an argument can be made
for evaluating pre- and post-treatment blood samples in
the same assay to provide internal controls. Thus, blood
samples often are shipped to centralized laboratories for
correlative studies where they are often cryopreserved
for later batch analysis. Another question is whether
cryopreservation should be done at each site, or whether
whole blood should be shipped to the central lab for
processing there. Several details of cryopreservation
methods can impact PBMC function and viability [30];
so if cell isolation and cryopreservation is done at each
site, there needs to be intensive training and quality
assurance to confirm comparable methods and results.
Though it is an option, this approach often is infeasible
for financial and organizational reasons. Thus, it is com-
mon for whole blood to be shipped from multiple sites
to a central laboratory for PBMC isolation and cryopre-
servation, for later analysis. However, the possible
impact of temperature during shipping, and prior to
processing, has not been systematically addressed. In
this study, we have focused on the effect of temperature
during shipping to assess its variation based on season
of the year, and to assess the impact of temperature on
PBMC viability and function.
In multiple studies in the HIV literature, delayed pro-
cessing of whole blood has been identified as a major
factor affecting PBMC performance in cell-based immu-
nological assays [26-29]. Delay in processing during
overnight shipping (at least 24 h) decreased responses to
microbial antigens in lymphoproliferative assays [12]
indicating the need for defined transportation conditions
for specific antigens. However, that study did not assess
the impact of temperature during shipping. The same
investigators also demonstrated that the way in which
frozen PBMC are thawed, and how long PBMC are
cryopreserved, will impact lymphoproliferative responses
to specific antigens [26]. Bull et al. found that the time
from phlebotomy to crypreservation should be less than
8 hours for optimal performance in cell based assays
such as ELIspot and intracellular cytokine staining
assays [27]. Delaying processing of whole blood by 6
hours also impaired the response of antigen-presenting
cells to Toll-like receptor ligands [40]. On the other
hand, Whiteside et al. [41] showed the phenotype and
function of dendritic cell populations derived from
apheresis products shipped overnight were not markedly
different from DC generated from cells immediately fro-
zen after elutriation. Smith et al. showed that delayed
processing of blood resulted in a decrease in cell viabi-
lity as well as a marked reduction in IFNg SFC in
response to varicella zoster antigen [29]; the presence of
DNase partially restored the response [42]. Kierstead et
al. [28] demonstrated that cryopreservation of PBMC
should be done within 12 hours of phlebotomy. How-
ever, in these two prior studies, the whole blood [29] or
Table 2 Pre-warmed gel packs extend the time above
15°C when shipping at cold temperatures
Outside Temperature Gel Pack Temperature Hours
Safe-Guard JVI
4°C 37°C 3.5 4.5
RT 1.8 2.0
Ambient 37°C 3.4 5.9
RT 2.5 3.2
Gel packs pre-warmed at RT or 37°C were packed inside blood specimen
shipping containers along with probes to measure the internal and
temperature after sitting overnight in a constant 4°C cold room or outdoors
where temperatures fell below freezing. The number of hours the internal
temperature remained above 15°C is show.
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Figure 7 Temperature performance test of the JVI Control
Temp shipping container. Five vials, filled with water conditioned
at 20°C, were suspended inside the foam vial holder and placed
inside the plastic clamshell plastic box fitted with small foam pads.
Two of the vials each had a T thermocouple taped to it. The
clamshell package was put inside the insulated corrugated cardboard
box in which two 12 oz. Control Temp gel packs conditioned at 20°C
were also placed inside and taped shut. The shipping container was
set inside a 45°C chamber for forty-five hours and the internal
package temperature recorded as described in Methods. The red line
indicates the external temperature of the chamber. The blue line
represents the average internal temperature of the shipping
container obtained from duplicate temperature probes.
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before cryopreservation. It is not known whether there
were negative effects from storing or shipping at 4°C.
Our data show that there is better viability, cell yield,
and function when cells are shipped at room tempera-
ture (22°C) or 30°C than at 15°C, and it is generally
accepted that storage of whole blood at 4°C negatively
impacts cell viability [5], function [29], and population
recovery [6,7,43,44]. Acknowledging the range of data in
the literature, in a separate study, we are also evaluating
the function of PBMC processed the same day (< 8 h)
or after overnight shipping or storage (manuscript in
preparation). However the current manuscript focuses
on the impact of temperature during shipping in those
cases when overnight shipping is necessary.
In some prior studies, statistical differences between
immediate and delayed processing of specimens were
i n f l u e n c e dn o to n l yb yt h ed e l a yi np r o c e s s i n gb u ta l s o
by the method of processing and by the type of antic-
oagulant used [27]. Thus, although there was a statis-
tical decrease in viability and recovery when whole
blood was collected in heparin and isolated by Accus-
pin technology (centrifuge tube divided into two
chambers by means of a porous high-density polyethy-
lene barrier, known as a frit), no significant decrease
was evident when PBMC were collected at the inter-
face of plasma and Ficoll. Similarly, significant differ-
ences in viability (but not recovery) between fresh and
delayed samples were evident when collected in ACD
or EDTA anticoagulants but not in heparin when
PBMC were isolated directly onto a Ficoll cushion.
Furthermore, the functionality of PBMC was not sig-
nificantly impaired by either method when measured
in an IFNg-ELIspot assay in response to the CEF pool
of peptides.
The observations leading to the present study come
from the multi-center clinical trials we have conducted
at the University of Virginia in collaboration with Can-
cer centers in Houston TX and Philadelphia PA. Blood
specimens shipped from these locations encounter
extreme seasonal climate conditions. On the other hand,
blood specimens at the on-site location are, for the
most part, collected, stored and processed with no expo-
sure to extreme temperatures and processed either on
the same day or after storage overnight at room tem-
perature. This study has addressed 1) the seasonal
changes in temperature inside packages of blood speci-
mens during shipping in the U.S., 2) changes in tem-
perature inside packages simulating hot or cold ambient
temperatures during shipping, and 3) the effects of tem-
peratures above and below room temperature on PBMC
numbers, viability, and function. These studies are rele-
vant to shipping blood specimens for correlative studies
in many settings.
We are not aware of prior work tracking temperature
ranges encountered within blood shipping containers or
their variation by season of the year. We found that
shipping of blood in insulated containers by contracted
overnight carriers is associated with large seasonal varia-
tions in temperature inside the packaging, ranging from
-1°C in winter to 35°C in summer, with most in the
range of 4°-32°C. Thus, blood samples in transit are fre-
quently exposed to high temperatures at or above 30°C
and low temperatures that approach or go below freez-
ing temperatures at least transiently. The monitoring
devices used in these shipments recorded the minimum
and maximum temperatures but not the duration of
each temperature. Thus, we also studied the changes
over time in a dynamic manner in hot or cold condi-
tions designed to mimic changes that may occur during
shipping, and found that insulation maintains internal
temperature below 30°C for up to 21 hours in ambient
temperatures that likely exceed those experienced dur-
ing shipping (45°C). We found in very cold ambient
conditions, that the insulated containers maintained the
internal temperatures above 15°C for almost 6 hours
and above 20°C for over 3 hours, with the aid of thermal
packs pre-warmed at 37°C.
We have found that incubation of whole blood at 50°C
caused unacceptably high loss of PBMC (data not
shown). Storage at 15°C or 40°C for 12 h causes signifi-
cant decreases in cell yields, viability and/or function
but exposure to those temperatures for 2 hours, or in
some cases even 8 hours is associated with PBMC
yields, viability and function comparable to those found
from blood stored at RT. The apoptosis rates in this
study of about 30-35% in thawed cells incubated over-
night are higher than observed in prior work where
apoptosis was measured directly after thawing [32]. It is
not uncommon, however, that cells undergo a delayed-
onset cell death (reviewed by Baust [39]) which may
account for the increase in apoptosis measured here.
Other studies also confirm that the total viability
decreases after overnight incubation [28]. Regardless, we
find that there is function in the PBMC that are viable
after overnight incubation.I n c u b a t i o na t1 5o r3 0 ° Ci s
associated with comparable T cell function assessed by
ELIspot assay to that seen with PBMC stored at RT.
Interestingly, we found that incubation at 30°C for peri-
ods up to 12 h was even associated with equivalent or
better yields, viability and function compared to samples
left at RT. However, incubation at 15°C or 40°C for 8-12
h was associated with decreased viability and function.
Colder temperature (15°C) primarily affected cell yield
after Ficoll separation and reduced recovery following
cryopreservation. Recovery may be due to a perturbation
in cell density [7] or formation of cell aggregates [5,45].
No increase in apoptosis relative to that seen when
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lower temperatures which is consistent with other data
showing reduced apoptotic rate of PBMC held at 4°C
for 24 hours [46].
We currently endeavor to keep samples in the range
of 20-30°C during shipping. In winter months, it helps
to start with samples warm (e.g. 37°C) and we recom-
mend shipping blood at 30-37°C, and recommend
including a “warm pack” at 37°C in the container, which
we found provides an extra 1-2 hours protection from
extreme cold during winter ambient conditions
(Table 3). On the other hand, during summer months,
we recommend shipping at RT, to allow for some
increase before exceeding 30°C. Inclusion of a fluid pack
at RT may also help to buffer the temperature changes
during shipping in the summer.
We propose that controlled and monitored shipping
temperatures may mitigate negative effects of shipping
blood in multicenter trials. Careful attention to the ship-
ping containers and testing in ambient temperature is
recommended. Certainly one way to prevent negative
effects of cold or hot temperatures during shipping of
blood specimens is to isolate PBMC or other cellular
elements prior to shipping, and either to cryopreserve
them or to assay them on site. This introduces other
sources of error and substantial costs, by the need to
maintain quality control assay validation across multiple
laboratories, which is problematic. We believe there is a
role for shipping blood specimens for centralized assays
where those assays can be performed in batches with
appropriate controls, but attention to details of shipping
conditions are warranted in such circumstances, to max-
imize the reliability of the results. It also is appropriate,
in multicenter trials, to stratify patients by institution to
control for systematic variations in temperature during
shipping that may be encountered depending on the
latitude of the institution and the shipping distance.
Conclusions
Blood packages shipped overnight by commercial carrier
may encounter extreme seasonal temperatures. Warmer
temperatures favor greater cell yields of shipped blood
specimens whereas colder temperatures for long periods
of time lower cell recovery and viability. Temperatures
≥40C for ≥8 hours reduces cell viability and functional-
ity after cryo-preservation. In the design of containers
for blood shipment, maintaining an ambient tempera-
ture between 22°C and 30°C should be considered.
Additional material
Additional file 1: Comparable cell numbers were derived from
complete and differential blood counts at each of the 3 hospital
trial centers participating in this study. The mean, median, 25
th and
75
th quartiles for lymphocyte and monocyte populations in the
peripheral blood are presented. Values are expressed as million of cells
per mL of blood. 1-Virginia; 7-Texas; 9-Pennsylvania.
Additional file 2: Flow diagram depicting the sequence of events in
the in Vitro study on time and temperature of whole blood storage
prior to cryopreservation and functional analysis. Approximately 60
mL of whole blood from six healthy donors were collected into
heparinized vacutainers. Aliquots were divided equally among ten
conditions: nine experimental conditions in which blood was exposed to
various temperatures for a defined length of time, then placed at RT (22°
C) for the remainder of the 24 h storage period and one reference
condition in which whole blood was stored overnight at RT. After
storage, PBMC were collected after Ficoll separation, counted and
cryopreserved. After 1-4 weeks, PBMC were removed for liquid nitrogen
and cell recovery, viability, phenotype, and function were determined.
Additional file 3: Proportions of CD4 and CD8 populations in PBMC
did not change under various temperature conditions, compared to
RT control conditions. Blood from 6 normal donors was incubated 24 h
at RT (22°C, control), and for 2-12 h at 15, 22, 30 or 40°C (Exptl), then RT
for the remainder of 24 h. PBMC were harvested, cryo-preserved, and
then thawed at least 1 week later. Samples were stained with
fluorescently labeled anti-CD3, anti-CD4 and anti-CD8 antibodies before
flow cytometric analysis. The proportion of CD4
+ cells among PBMC was
measured as the number of CD3
+CD4
+ cells divided by the total PBMC.
Similarly, the proportion of CD8+ cells among PBMC was measured as
the number of CD3
+CD8
+ cells divided by the total PBMC. The ratios of
these CD4 and CD8 proportions are reported in this table, for each
temperature condition, compared to control samples left at RT for 24 h.
The estimated means, 95% confidence intervals and p-value of these
ratios are shown for CD4 and CD8 populations.
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